NeuroTherapeutics raises $43 million series B with strong pharma backing
This article was originally published in Scrip
NeuroTherapeutics Pharma has attracted funding from Pfizer and GlaxoSmithKline's corporate venture arm in its latest investment round. The Chicago, Illinois-based firm raised $43 million in a series B financing that included new investors Fidelity Biosciences, MPM Capital and SR One (GSK's venture arm), which co-led the transaction, and Pfizer. Existing investors Novo Ventures and Thomas McNerney & Partners also participated.